Tag: Eftilagimod Alpha
Immutep gets green light for large-scale cancer product manufacturing for clinical trials
Immutep Limited, a clinical-stage biotechnology company specialising in LAG-3 immunotherapies for cancer and autoimmune diseases, has received regulatory authorisation for the commercial manufacturing of Eftilagimod Alpha (efti) at a scale of 2,000 litres for clinical trial use.
Featured Article
How a small pet food manufacturer supports a 5x increase in production capacity
For Advanced Pet Care of Australia, scaling into one of Australia’s top pet food manufacturers required more than new production capacity – it required better systems.
